DeNDRoN and NIHR Logos DeNDRoN Home Page www.nihr.ac.uk

  • Home
  • Research Networks
    • East Anglia
    • North East
    • North West
    • North Thames
    • South Coast
    • South West
    • Thames Valley
    • Supplementary Resources
  • Clinical Research
    • Aims & Objectives
    • Structure & Accountability
    • Membership Responsibilities
    • Dementias
    • Huntington's disease
    • Motor Neurone Disease
    • Neuropathology & Brain Banking
    • Parkinson's disease
    • Primary Care
    • Methodology SIG
  • Patient and Public Involvement
    • Aims & Objectives
    • Background
    • Co-ordination
    • PPI Forum
    • Principles
    • What does PPI mean?
    • PPI Working Group
    • Registering your interest
  • Industry
    • Adoption
    • Background
    • Benefits
    • Collaboration
    • FAQ
    • Industry Support
    • NIHR industry documents
    • Non-commercial
    • NIHR Industry
  • News
  • Events
  • Vacancies
  • About
    • CC Contacts
    • Conferences
    • Portal

The Same Page - DeNDRoN Newsletter

Winter 2009/2010 pdf

Spring 2009 pdf

December 2008 pdf

September 2008 pdf

July 2008 pdf

 

 

 

 


Links

DeNDRoN Portal

NIHR CRN Co-ordinating Centre

NIHR

DeNDRoN Portfolio

MND Patient Record of Interest in Research

DeNDRoN Conference 2009

Non-Commercial Portfolio Submission form

NIHR Portfolio Eligibility Criteria

University College London

Newcastle University

 

Over 2,100 people recruited to UK’s largest Parkinson’s disease trial


22 December 2009

PD MED

The UK’s largest trial in Parkinson’s disease, PD MED, closed in December with over 2100 people recruited. The DeNDRoN Local Research Networks played a key role in delivering this trial, as the PD MED trial team from Birmingham University presented at the 2008 international movement disorders conference.

PD MED is recruiting from 97 NHS hospitals across the country and started in 2000. Up to May 2007, 60% and 40% of patients had been recruited from areas of the country supported by DeNDRoN LRNs and not supported respectively. Recruitment had been falling in all areas in 2006 but this decline was reversed in DeNDRoN, but not in non-DeNDRoN, areas from 2007 onwards when the DeNDRoN LRNs became operational. From May 2007 to December 2009 80% of patients were recruited in DeNDRoN supported areas.

DeNDRoN Co-ordinating Centre Assistant Director, Piers Kotting said: “The key issue raised by PIs when contacted by DeNDRoN LRNs in 2007 was the lack of local funding for the trial. Since research costs were fully met through the HTA grant and no excess treatment costs were identified in the trial, the problem was that the NHS Service Support costs that should have been available to support activity at each of the sites were not getting to where they needed to be under the old Culyer system. DeNDRoN has been able to provide the necessary service support costs at sites within its LRNs and recruitment has doubled. This shows that the Clinical Research Network model can be highly effective.“

Notes

The PD MED trial is an NIHR-funded, multi-centre randomised controlled trial comparing the efficacy and long-term cost-effectiveness of different classes of drug for early and advanced Parkinson’s disease (PD).
Further information can be found at: http://www.pdmed.bham.ac.uk/index.shtml

Contacts

NIHR DeNDRoN enquiries
news@dendron.org.uk

PD MED enquiries
PDTrials@bham.ac.uk



London Office (General Enquiries)
DeNDRoN Co-ordinating Centre
Wolfson Centre
Mecklenburgh Square
LONDON
WC1N 2AP

Tel: +44 (0)20 7905 2995
Fax: +44 (0)20 7905 2959



Back to top

Newcastle Office (Portfolio Enquiries)
Wolfson Research Centre
Institute for Ageing and Health
Newcastle University
Campus for Ageing and Vitality
NEWCASTLE UPON TYNE
NE4 5PL
Tel:  +44 (0)191 248 1347
Fax: +44 (0)191 248 1301

© DeNDRoN 2010



info@dendron.org.uk